Apellis Pharmaceuticals, Inc. (APLS)
After hours:
Chart Events
Performance Outlook
| Previous Close | 44.48 |
| Open | 45.03 |
| Bid | 42.65 x 1200 |
| Ask | 42.70 x 800 |
| Day's Range | 42.62 - 45.81 |
| 52 Week Range | 27.50 - 73.00 |
| Volume | |
| Avg. Volume | 1,234,812 |
| Market Cap | 4.148B |
| Beta (5Y Monthly) | 1.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.47 |
| Earnings Date | Apr 26, 2022 - May 02, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 72.00 |
- GlobeNewswire
Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Association Congress
Accepted abstracts include an oral presentation highlighting quality of life improvements with EMPAVELI® (pegcetacoplan) WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that seven abstracts will be presented at the hybrid European Hematology Association (EHA) Congress to be held June 9-12 in Vienna, Austria. Data to be presented reinforce the robust efficacy and safety prof
- GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to four new employees with a grant date of May 2, 2022, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2022 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company. T
- Zacks
Apellis (APLS) Hit By Wider-Than-Expected Q1 Loss, Revenues Top
Apellis' (APLS) earnings missed estimates in the first quarter of 2022, while revenues surpassed expectations.
